证券代码：688621 证券简称：阳光诺和 公告编号：2025-063 北京阳光诺和药物研究股份有限公司 关于筹划发行股份及可转换公司债券购买资产并募 集配套资金暨关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 员会第十七次会议、第二届董事会战略与 ESG 委员会第八次会议、第二届董事 会独立董事专门会议第六次会议审议通过了《关于公司发行股份及可转换公司债 券购买资产并募集配套资金暨关联交易方案的议案》《关于<北京阳光诺和药物 研究股份有限公司发行股份及可转换公司债券购买资产并募集配套资金暨关联 交易预案>及其摘要的议案》等与本次交易相关的议案。同日，公司向上海证券 交易所申请公司股票于 2025 年 5 月 13 日开市起复牌。具体内容详见公司于 2025 年 5 月 13 日刊登在上海证券交易所网站（www.sse.com.cn）的《北京阳光诺和 药物研究股份有限公司发行股份及可转换公司债券购买资产并募集配套资金暨 关联交易预案》《北京阳光诺和药物研究股份有限公司关于披露重大资产重组预 案的一般 ...

1 证券代码：688621 证券简称：阳光诺和 公告编号：2025-064 北京阳光诺和药物研究股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京阳光诺和药物研究股份有限公司 首次公开发行股票注册的批复》（证监许可【2021】1629 号），同意公司首次 公开发行股票的注册申请，公司获准向社会公开发行人民币普通股 20,000,000 股。 每股面值为1元，每股发行价格为26.89元，本次发行募集资金总额537,800,000.00 元。上述募集资金总额扣除发行费用 70,618,507.55 元（相关费用均为不含税金 额）后，本次公司公开发行新股的募集资金净额 467,181,492.45 元，民生证券股 份有限公司已于 2021 年 6 月 16 日将扣除相关承销保荐费（不含税）人民币 47,402,000.00 元后的余款人民币 490,398,000.00 元汇入公司募集资金专户，大华 会计师事务所（特殊普通 ...

Group 1 - The innovative drug concept stocks experienced significant upward movement, with Rundu Co., Ltd. hitting the daily limit increase [1] - Haitian Pharmaceutical and Sunshine Nuohuo both rose over 10%, indicating strong market interest [1] - Other companies such as Huaren Health, Fuyuan Pharmaceutical, and Guangsheng Tang also saw notable gains, reflecting a broader trend in the sector [1]

Core Viewpoint - Sunshine Nuohuo's stock price experienced a decline on August 5, closing at 64.33 yuan, down by 2.21 yuan from the previous trading day [1] Company Overview - Sunshine Nuohuo is focused on the medical services sector, with operations including pharmaceutical research and clinical trials. The company is headquartered in Beijing and holds a significant market position in the pharmaceutical research service field [1] Stock Performance - On August 5, the opening price was 66.00 yuan, with a highest price of 66.00 yuan and a lowest price of 63.45 yuan. The trading volume was 62,636 hands, with a transaction amount of 403 million yuan [1] - The company currently has a price-to-earnings (P/E) ratio of 60.90 times and a price-to-book (P/B) ratio of 7.12 times [1] Capital Flow - On August 5, the net outflow of main funds for Sunshine Nuohuo was 31.608 million yuan, with a cumulative net outflow of 99.2964 million yuan over the past five trading days [1]

阳光诺和最新一期业绩显示，截至2025一季报，公司营业总收入2.31亿元、同比减少8.49%，归属净利 润2957.86万元，同比减少59.34%，扣非净利润2020.48万元，同比减少69.67%，流动比率1.635、速动比 率1.621、资产负债率51.76%。 金融界消息 截至2025年8月5日收盘，阳光诺和（688621）报收于64.33元，下跌3.32%，换手率5.59%， 成交量6.26万手，成交金额4.03亿元。 通过天眼查大数据分析，北京阳光诺和药物研究股份有限公司共对外投资了20家企业，参与招投标项目 25次，知识产权方面有商标信息25条，专利信息91条，此外企业还拥有行政许可22个。 资金流向方面，今日主力资金净流出3160.80万元，占比成交额7.85%。其中，超大单净流出2094.22万 元、占成交额5.2%，大单净流出1066.58万元、占成交额2.65%，中单净流出流入2102.46万元、占成交 额5.22%，小单净流入1058.34万元、占成交额2.63%。 来源：金融界 天眼查商业履历信息显示，北京阳光诺和药物研究股份有限公司，成立于2009年，位于北京市，是一家 以从事研究和 ...

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

A股创新药概念股局部反弹，翰宇药业午后直线拉升涨超10%，海辰药业、阳光诺和、广生堂涨超 10%，福源医药、万泽股份涨停，陇神戎发、京新药业、常山药业、舒泰神等跟涨。 ...

Group 1 - The artificial intelligence sector experienced significant stock price increases, with companies like Kesi Technology and Dongjie Intelligent reaching a 20% limit up, while others like Shanhai Intelligent and Nengke Technology also hit the limit up [1][2] - Notable stock performances included Wanlima at +14.72%, Jinxian Modern at +14.66%, and Yangguang Nuohe at +13.95%, indicating strong investor interest in AI-related companies [2] Group 2 - The State Council meeting on July 31 approved the "Deepening the Implementation of 'Artificial Intelligence+' Action Opinions," emphasizing the need for large-scale commercialization of AI applications across various sectors [3] - The policy aims to create a virtuous cycle of innovation and application, with government and state-owned enterprises leading by example and supporting technology implementation through open scenarios [3] - The report from Zhonghang Securities highlights that the AI industry is entering a value release window, with 2025 expected to mark the year of AI application landing, driven by advancements in general large model technology [3] - Investment focus is recommended on two main lines: (1) developers of large models and AI agent capabilities, and (2) applications of AI in real-world scenarios [3]

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. is currently involved in litigation with Hunan Hengsheng Pharmaceutical Co., Ltd., with the total amount in dispute reaching approximately 48 million yuan, but the company does not expect this to negatively impact its profits due to prior provisions made for bad debts [2][10]. Group 1: Litigation Details - The case is currently in the first-instance stage, with the company acting as both a counterclaim plaintiff and a new lawsuit plaintiff [2]. - The total amount involved in the litigation includes a counterclaim amount of 7,407,283.51 yuan and a new lawsuit amount of 40,670,942.46 yuan, totaling 48,078,225.97 yuan [2]. - The company has filed a counterclaim against Hengsheng Pharmaceutical, asserting that the latter has failed to pay the agreed research fees as per their contract [5][6]. Group 2: Contractual Obligations - The counterclaim is based on a technical development contract signed on March 28, 2018, where the company assisted Hengsheng in developing a drug and was to be compensated accordingly [5][6]. - The company has also initiated a new lawsuit regarding 24 other technical development contracts, citing Hengsheng's failure to pay the agreed fees [7][8]. Group 3: Financial Impact - The company has fully provisioned for bad debts related to Hengsheng's accounts receivable and contract assets, indicating that the litigation will not adversely affect current or future profits [10]. - The company will continue to monitor the litigation's progress and fulfill its disclosure obligations to investors [10].

北京阳光诺和药物研究股份有限公司 关于公司诉讼事项进展暨提起新诉讼的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688621 证券简称：阳光诺和 公告编号：2025-061 案件所处的诉讼阶段：一审立案 上市公司所处的当事人地位：反诉原告及新增诉讼原告 涉案的金额：反诉涉案金额为 7,407,283.51 元；新增诉讼涉案金额为 40,670,942.46 元，合计 48,078,225.97 元。 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对湖南恒生制药股份有限公司（以下简称"恒生制药"）应收账 款和合同资产全额计提了坏账准备，因此该诉讼事项对公司当期及期 后利润不会构成负面影响。鉴于本次诉讼案件尚未开庭审理，公司将 根据该案件的诉讼进展情况及时履行信息披露义务，敬请广大投资者 注意投资风险。 提起诉讼。 截至本公告披露日，上述案件已立案，尚未开庭审理。 二、诉讼案件的基本情况 （一）反诉案件的基本情况 （1）诉讼当事人 反诉原告：北京阳光诺和药物研究股份有限 ...